Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab in Refractory or Relapsed Multiple Myeloma
NCT00368121Phase 2Terminated
- Start
- Aug 2006
- Primary completion
- Jun 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in multiple myeloma (MM). Primary endpoint: Overall Response Rate at 16 weeks. Started Aug 2006; status: terminated.
02
Drugs
KL-140
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00368121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00368121.